3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Urinary Bladder Neoplasms
1
Surgery
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Ductal Adenocarcinoma
1
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
1
Multiple Myeloma
1
Medulloblastoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
HER2-positive Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Cancer Invasive
1
Interventions
Carboplatin
29
pembrolizumab
25
Pemetrexed
25
Specimen Handling
22
Cisplatin
20
Magnetic Resonance Spectroscopy
18
Paclitaxel
15
Gemcitabine
13
Docetaxel
12
durvalumab
9
Nivolumab
8
osimertinib
7
Taxes
7
Immunoglobulin G
7
Disulfides
7
130-nm albumin-bound paclitaxel
7
atezolizumab
6
Etoposide
6
Platinum
5
Cetuximab
5
1,2-diaminocyclohexaneplatinum II citrate
5
X-Rays
4
Ramucirumab
4
Radiotherapy
4
Radiation
4
Observation
4
Interviews as Topic
4
Biopsy
4
Albumin-Bound Paclitaxel
4
patritumab deruxtecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Neoadjuvant Therapy
×
30 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled